Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 129   

Articles published

NVO 44.29 0.00 (0.00%)
price chart
Novo Nordisk's (NVO) Diabetes Drug Victoza Receives Positive Review By CHMP
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Friday that its key drug Victoza has received positive reviews from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes ...
Related articles »  
Novo Nordisk A/S (ADR) (NVO), Colgate-Palmolive Company (CL), and ...
The pharmaceutical company has a second quarter net profit margin of 32.34% and reported a 44.20% return on average assets and a 79.87% return on average equity.
Lars Rebien Sorensen: The Man Behind Novo Nordisk
Sorensen's ability to lead a healthcare company was put to test just six months into his job as Novo Nordisk's A/S (ADR) (NVO) CEO. The company had received a lot of heat for suing the South African government in a patent fight related to drugs that ...
Related articles »  
Novo Nordisk And Eli Lilly Battling To Win GLP-1 Drug Market
Eli Lilly and Co's (LLY) new GLP-1 drug Trulicity was approved by the US Food and Drug Administration (FDA) last week, and will now challenge Victoza's position.
Related articles »  
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »  
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Novo Nordisk A/S (ADR) (NVO) announced yesterday, that its insulin therapy Tresiba, which was in late-stage trials, has proved to be safe and effective for the treatment of type 1 diabetes in children and young adults.
Related articles »  
Sizzling news - AmerisourceBergen (NYSE:ABC), Novo Nordisk A/S (ADR ...
Manhattan, NY- 31 October, 2014 - (Techsonian) - AmerisourceBergen Corp. (NYSE:ABC) declared that in its fiscal year 2014 third quarter ended June 30, 2014, adjusted diluted earnings each share from continuing operations surged 29.5% percent to ...
Related articles »  
Novo Nordisk A/S (ADR) (NVO): A Company Solving The Global Diabetes Crisis ...
Novo Nordisk A/S (NYSE: NVO) is the undisputed global leader in the diabetes market. The company's impressive product portfolio is home to five of the world's 10 best-selling diabetes medications.
Related articles »  
Traders Recap: Novo Nordisk A/S (ADR) (NYSE:NVO), Holcim (OTCMKTS ...
Novo Nordisk A/S (ADR) (NYSE:NVO) started its trading session with the price of $43.04 and closed at $43.30 by losing -0.89%.
Related articles »  
Novo, Orexigen Join Race For Obesity Drugs; Arena-Eisai's Belviq And Vivus's ...
Novo Nordisk A/S (ADR) (NVO) received the Food and Drug Administration's (FDA) approval on September 11 for its weight-loss therapy Saxenda, which was earlier prescribed as a treatment for diabetes.
Related articles »